NK1 receptor fused to beta-arrestin displays a single-component, high-affinity molecular phenotype.

Mol Pharmacol

Laboratory for Molecular Pharmacology, Department of Pharmacology, The Panum Institute, University of Copenhagen, Denmark.

Published: July 2002

Arrestins are cytosolic proteins that, upon stimulation of seven transmembrane (7TM) receptors, terminate signaling by binding to the receptor, displacing the G protein and targeting the receptor to clathrin-coated pits. Fusion of beta-arrestin1 to the C-terminal end of the neurokinin NK1 receptor resulted in a chimeric protein that was expressed to some extent on the cell surface but also accumulated in transferrin-labeled recycling endosomes independently of agonist stimulation. As expected, the fusion protein was almost totally silenced with respect to agonist-induced signaling through the normal Gq/G11 and Gs pathways. The NK1-beta-arrestin1 fusion construct bound nonpeptide antagonists with increased affinity but surprisingly also bound two types of agonists, substance P and neurokinin A, with high, normal affinity. In the wild-type NK1 receptor, neurokinin A (NKA) competes for binding against substance P and especially against antagonists with up to 1000-fold lower apparent affinity than determined in functional assays and in homologous binding assays. When the NK1 receptor was closely fused to G proteins, this phenomenon was eliminated among agonists, but the agonists still competed with low affinity against antagonists. In contrast, in the NK1-beta-arrestin1 fusion protein, all ligands bound with similar affinity independent of the choice of radioligand and with Hill coefficients near unity. We conclude that the NK1 receptor in complex with arrestin is in a high-affinity, stable, agonist-binding form probably best suited to structural analysis and that the receptor can display binding properties that are nearly theoretically ideal when it is forced to complex with only a single intracellular protein partner.

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.62.1.30DOI Listing

Publication Analysis

Top Keywords

nk1 receptor
20
fusion protein
8
nk1-beta-arrestin1 fusion
8
receptor
7
nk1
5
protein
5
affinity
5
receptor fused
4
fused beta-arrestin
4
beta-arrestin displays
4

Similar Publications

Background/aim: Vascular pain associated with NK1 receptor antagonists, particularly fosaprepitant, remains a significant challenge in cancer chemotherapy. The present study investigated the incidence of vascular pain with the administration of fosaprepitant and fosnetupitant and assessed the psychological burden on nurses performing venipuncture.

Patients And Methods: We conducted a prospective observational study involving 115 cancer patients receiving NK1 receptor antagonists via peripheral venous catheters.

View Article and Find Full Text PDF

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database.

Sci Rep

December 2024

Department of Pharmacy, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, 215153, China.

Background: NK-1 receptor antagonists (NK-1RAs) are proven to be successful in preventing chemotherapy-induced nausea and vomiting (CINV). The safety profile of NK-1RAs has not been systematically analyzed in the real world. This pharmacovigilance study investigated the differences in adverse events (AEs) between NK-1RAs.

View Article and Find Full Text PDF

Magnesium-Phenolic Nanoeditor Refining Gliomatous T Cells for Metalloimmunotherapy.

ACS Nano

December 2024

Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China.

More than the sparse infiltration in glioblastoma, cytotoxic T lymphocytes (CTLs) also function inefficiently and overexpress the inhibitory markers, especially the identified NK cell receptor (NK1.1). However, most studies solely focus on how to augment tumor-infiltrating CTLs and overlook their killing maintenance.

View Article and Find Full Text PDF

Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231) with a modified murine cell line (E0771), both expressing luciferase.

View Article and Find Full Text PDF
Article Synopsis
  • Olanzapine is an atypical antipsychotic that helps prevent nausea and vomiting, particularly after highly emetogenic chemotherapy (HEC), but it can cause side effects like hyperglycemia and drowsiness.
  • A systematic review and meta-analysis assessed the effectiveness of olanzapine combined with standard triplet antiemetic therapy compared to triplet therapy alone, focusing on outcomes like nausea control and adverse effects.
  • Results showed that adding olanzapine significantly improved nausea and vomiting prevention in both acute and delayed phases with minimal adverse effects, indicating it can be beneficial for patients undergoing HEC.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!